DrugDashboards

Olmesartan medoxomil, amlodipine and hydrochlorothiazide

Olmesartan medoxomil, amlodipine and hydrochlorothiazide · OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1 · Tablet, Film Coated · Oral · Camber Pharmaceuticals, Inc.

NDC 31722-0895-30 · 30 TABLET, FILM COATED in 1 BOTTLE · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.5$1.00$1.50Jul 2026Sep 2026$1.13
2 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$33.97
#90 count
$101.90

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Supply fragility

20Low risk

Some pressure is visible, but not much — here’s everything the score found to count.

  • 2 active manufacturers+20

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for olmesartan medoxomil, amlodipine and hydrochlorothiazide (oral solid) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
ANDA209242
TE code
AB
Approval date
Oct 6, 2025
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Olmesartan medoxomil, amlodipine and hydrochlorothiazide (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
Camber Pharmaceuticals, Inc.OLMESARTAN MEDOXOMIL 20 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1Aug 26, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1Aug 26, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1Aug 26, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1Aug 26, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1Aug 26, 2026Sep 2, 2026
Teva Pharmaceuticals USA, Inc.OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1Aug 26, 2026Sep 2, 2026
Teva Pharmaceuticals USA, Inc.OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1Aug 26, 2026Sep 2, 2026
Teva Pharmaceuticals USA, Inc.OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1Aug 26, 2026Sep 2, 2026
Teva Pharmaceuticals USA, Inc.OLMESARTAN MEDOXOMIL 20 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1Aug 26, 2026Sep 2, 2026
Teva Pharmaceuticals USA, Inc.OLMESARTAN MEDOXOMIL 40 mg/1; AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1Aug 26, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.OLMESARTAN MEDOXOMIL 10 mg/1; AMLODIPINE BESYLATE 12.5 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1Jul 22, 2026Aug 19, 2026
Camber Pharmaceuticals, Inc.OLMESARTAN MEDOXOMIL 5 mg/1; AMLODIPINE BESYLATE 12.5 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1Jul 22, 2026Aug 19, 2026
Camber Pharmaceuticals, Inc.OLMESARTAN MEDOXOMIL 10 mg/1; AMLODIPINE BESYLATE 25 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1Jul 22, 2026Aug 19, 2026
Camber Pharmaceuticals, Inc.OLMESARTAN MEDOXOMIL 5 mg/1; AMLODIPINE BESYLATE 25 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1Jul 22, 2026Aug 19, 2026
Camber Pharmaceuticals, Inc.OLMESARTAN MEDOXOMIL 5 mg/1; AMLODIPINE BESYLATE 12.5 mg/1; HYDROCHLOROTHIAZIDE 20 mg/1Jul 22, 2026Aug 19, 2026
Teva Pharmaceuticals USA, Inc.OLMESARTAN MEDOXOMIL 5 mg/1; AMLODIPINE BESYLATE 25 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1Jul 22, 2026Aug 19, 2026
Teva Pharmaceuticals USA, Inc.OLMESARTAN MEDOXOMIL 10 mg/1; AMLODIPINE BESYLATE 12.5 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1Jul 22, 2026Aug 19, 2026
Teva Pharmaceuticals USA, Inc.OLMESARTAN MEDOXOMIL 10 mg/1; AMLODIPINE BESYLATE 25 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1Jul 22, 2026Aug 19, 2026
Teva Pharmaceuticals USA, Inc.OLMESARTAN MEDOXOMIL 5 mg/1; AMLODIPINE BESYLATE 12.5 mg/1; HYDROCHLOROTHIAZIDE 20 mg/1Jul 22, 2026Aug 19, 2026
Teva Pharmaceuticals USA, Inc.OLMESARTAN MEDOXOMIL 5 mg/1; AMLODIPINE BESYLATE 12.5 mg/1; HYDROCHLOROTHIAZIDE 40 mg/1Jul 22, 2026Aug 19, 2026
Camber Pharmaceuticals, Inc.AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1Jul 15, 2026Jul 15, 2026
Camber Pharmaceuticals, Inc.AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1Jul 15, 2026Jul 15, 2026
Camber Pharmaceuticals, Inc.AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1Jul 15, 2026Jul 15, 2026
Camber Pharmaceuticals, Inc.AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1Jul 15, 2026Jul 15, 2026
Camber Pharmaceuticals, Inc.AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1Jul 15, 2026Jul 15, 2026
Teva Pharmaceuticals USA, Inc.AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1Jul 15, 2026Jul 15, 2026
Teva Pharmaceuticals USA, Inc.AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 20 mg/1Jul 15, 2026Jul 15, 2026
Teva Pharmaceuticals USA, Inc.AMLODIPINE BESYLATE 10 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1Jul 15, 2026Jul 15, 2026
Teva Pharmaceuticals USA, Inc.AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 12.5 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1Jul 15, 2026Jul 15, 2026
Teva Pharmaceuticals USA, Inc.AMLODIPINE BESYLATE 5 mg/1; HYDROCHLOROTHIAZIDE 25 mg/1; OLMESARTAN MEDOXOMIL 40 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Olmesartan medoxomil, amlodipine and hydrochlorothiazide — NDC 31722-0895-30," retrieved September 3, 2026, https://drugdashboards.com/drug/31722089530.

Free to cite with attribution — see how the data is put together.